OncoMatch/Clinical Trials/NCT06551142
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
Is NCT06551142 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for neoplasms.
Treatment: GSK5764227 · Cisplatin · Carboplatin · Atezolizumab · Pembrolizumab · Durvalumab · Cetuximab · Bevacizumab — The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CD276 any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7-H3 targeted therapy (orlotamab, enoblituzumab, I-Dxd)
Prior treatment with orlotamab, enoblituzumab, I-Dxd, or other B7-H3 targeted agents.
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
QTc ≤450 msec (≤480 msec for bundle branch block); no clinically significant arrhythmias or ECG abnormalities; LVEF ≥50%
Has adequate organ function. Has QT interval, corrected for heart rate (QTc) >450 msec or QTc >480 msec for participants with bundle branch block. Evidence of current clinically significant arrhythmias or ECG abnormalities (e.g., complete left bundle branch block, third-degree atrioventricular [AV] block, second-degree AV block, PR interval >250 msec). Left ventricular ejection fraction (LVEF) <50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Stanford, California
- GSK Investigational Site · Denver, Colorado
- GSK Investigational Site · New Haven, Connecticut
- GSK Investigational Site · Boston, Massachusetts
- GSK Investigational Site · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify